Home > Healthcare > Pharmaceuticals > Finished Drug Form > Joint Pain Injections Market

Joint Pain Injections Market Trends

Report ID: GMI5403
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Joint Pain Injections Market Trends

The surging prevalence of orthopedic disorders, including osteoarthritis, osteoporosis, and joint fractures, is projected to fuel the growth of the market.
Osteoarthritis, an increasingly common joint disorder, affects a significant proportion of the population worldwide. With an aging population and rising life expectancy, the prevalence of osteoarthritis is steadily increasing, particularly in emerging markets.
According to the Global RA Network in 2021, approximately 350 million people worldwide suffer from arthritis. The CDC reports that currently, around 1 in 4 (or 54.4 million) adults in the U.S. experience some form of arthritis, with this number projected to reach 78 million by 2040.
Additionally, data from the IHME Global Burden of Disease Study 2019 indicates that over 57 million people in Western Europe have osteoarthritis. In 2019, osteoarthritis affected over 11 million people in Germany, 8.6 million in Italy, 8.5 million in the UK, 8.4 million in France, 6.6 million in Spain, and 1 million in Sweden.
This number is expected to surge significantly in the coming years, further driving demand for joint pain injections.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global joint pain injections industry was valued at USD 3.6 billion in 2023 and is anticipated to grow at a 7.7% CAGR from 2024 to 2032, driven by an increasing elderly population and a rise in orthopedic issues.

The hyaluronic acid injections segment held a 64.8% revenue share in 2023 and is projected to expand at a 7.9% CAGR during the forecast period due to the aging population and the development of technologically advanced products.

The North America joint pain injections industry held a 47.4% share in 2023 and is set to witness substantial growth, primarily due to the increasing prevalence of arthritis and other bone-related issues, coupled with the rapid adoption of new products.

Key players in the industry include Anika Therapeutics, Inc., Arthrex, Bioventus, Emcyte Corporation, Ferring B.V., Lifecore Biomedical, OrthogenRx, Pacira BioSciences (Flexion), and Pfizer, Inc.